Phenotypic features of children with neurodevelopmental diseases in relation to biogenic amines

Respir Physiol Neurobiol. 2015 Apr:209:124-32. doi: 10.1016/j.resp.2014.12.007. Epub 2014 Dec 13.

Abstract

Disruption of monoamines metabolism leads to diverse manifestations, including developmental, movement and respiratory dysfunctions. We aimed to correlate clinical phenotypes of 55 children with neurodevelopmental disorders with dopamine (HVA) and serotonin (5-HIIA) metabolites in CSF. Decreased level of at least one metabolite was documented in 49.1% patients. Both metabolites were significantly lower in progressive disorder and extrapyramidal syndrome (p<0.05). HVA was significantly lower in hypokinetic and regulatory disorders (p<0.05). In univariate analysis, only progressive course, extrapyramidal syndrome and dystonia were significantly associated with decreased 5-HIAA. In multivariate regression only progressive course remained significant (p=0.005). Progressive disease, extrapyramidal syndrome, dystonia, tremor and rigidity were positively associated with low HVA. In multivariate analysis only: progressive course and rigidity remained significant. Progressive/rigid phenotype carries a high risk of monoamines deficiency, strongly implying need for their analysis. Psychomotor delay with epilepsy and hypotonia is rarely linked to low monoamines level. Irrespective of final diagnosis, different clinical presentations may be associated with impaired monoamines turnover.

Keywords: Biogenic amines; Children; Dopamine; Neurodevelopmental syndrome; Phenotype; Serotonin.

MeSH terms

  • Adolescent
  • Adult
  • Biogenic Amines / cerebrospinal fluid*
  • Child
  • Child, Preschool
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Humans
  • Infant
  • Logistic Models
  • Male
  • Multivariate Analysis
  • Neurodevelopmental Disorders / diagnosis
  • Neurodevelopmental Disorders / physiopathology*
  • Neurodevelopmental Disorders / therapy
  • Phenotype*
  • Young Adult

Substances

  • Biogenic Amines